TORRENT PHARMACEUTICALS LNSE: TORNTPHARMBSE: 500420Healthcare · Pharmaceuticals

₹4,580.0023.00 (0.50%)

Mkt Cap: ₹1.74 L Cr.
P/E (TTM): 74.80
Open: ₹4,540.00
Day's Range: ₹4,525.30 – ₹4,610.90
52W Range: ₹3,532.60 – ₹5,250.00
Div Yield: 0.83%
EPS (TTM): ₹14.04
Book Value: ₹462.32

TORRENT PHARMACEUTICALS L Financial Statements

Name: TORRENT PHARMACEUTICALS L Financials — historical data
Creator: StockeZee

For May 2026, TORRENT PHARMACEUTICALS L reported revenue of ₹13,980 crore and net profit of ₹2,163 crore. Return on equity stands at 12.16%. Profit & loss, balance sheet and cash flow across 18 reported years are below.

Updated 30 Oct 2026Source: NSE & BSE company filingsNifty 100 constituent

Latest year revenue: ₹13,980 Cr
EBITDA: ₹4,559 Cr
Operating margin: 32.61%
Profit after tax: ₹2,163 Cr
Net margin: 15.47%
EPS: ₹63.91
Latest year: May 2026
Years reported: 18

TORRENT PHARMACEUTICALS L revenue and profit trend

The quickest view of reported annual business performance. Revenue and profit use separate scales.

TORRENT PHARMACEUTICALS L profit & loss

Reported annual performance for TORRENT PHARMACEUTICALS L, oldest to newest. Figures in ₹ crore unless a row states otherwise.

TORRENT PHARMACEUTICALS L annual profit and loss statement. Figures in ₹ crore unless a row states otherwise.
Line item	Mar 2022	May 2022	Mar 2023	May 2023	Mar 2024	May 2024	Mar 2025	May 2025	Mar 2026	May 2026
Revenue from Operations	8,508	8,508	9,620	9,620	10,728	10,728	11,516	11,516	13,980	13,980
Sales Growth YoY %	6.28%	6.28%	13.07%	13.07%	11.52%	11.52%	7.35%	7.35%	21.4%	21.4%
Other Income	197	197	45	45	58	58	23	23	-94	-94
Total Income	8,705	8,705	9,665	9,665	10,786	10,786	11,539	11,539	13,886	13,886
Cost of Goods Sold (COGS)	2,443	2,443	2,735	2,735	2,686	2,686	2,776	2,776	3,388	3,388
Cost of Materials Consumed	1,538	1,538	1,480	1,480	1,657	1,657	1,520	1,520	1,758	1,758
Purchases of Stock-in-Trade	831	831	1,089	1,089	1,184	1,184	1,531	1,531	1,619	1,619
Changes in Inventories	74	74	166	166	-155	-155	-275	-275	11	11
Gross Profit	6,065	6,065	6,885	6,885	8,042	8,042	8,740	8,740	10,592	10,592
Gross Margin %	71.29%	71.29%	71.57%	71.57%	74.96%	74.96%	75.89%	75.89%	75.77%	75.77%
Total Operating Expenses	3,634	3,634	4,043	4,043	4,674	4,674	5,019	5,019	6,033	6,033
Employee Benefit Expense	1,526	1,526	1,678	1,678	1,984	1,984	2,203	2,203	2,671	2,671
Other Expenses	2,108	2,108	2,365	2,365	2,690	2,690	2,816	2,816	3,362	3,362
EBITDA	2,431	2,431	2,842	2,842	3,368	3,368	3,721	3,721	4,559	4,559
OPM %	28.57%	28.57%	29.54%	29.54%	31.39%	31.39%	32.31%	32.31%	32.61%	32.61%
Total Non-Operating Expenses	432	432	1,040	1,040	1,250	1,250	1,023	1,023	1,415	1,415
Depreciation & Amortisation	662	662	707	707	808	808	795	795	1,119	1,119
Finance Costs	255	255	333	333	354	354	252	252	385	385
Exceptional Items (Before Tax)	-485	-485	0	0	88	88	-24	-24	-89	-89
Profit Before Tax (PBT)	1,226	1,226	1,847	1,847	2,352	2,352	2,673	2,673	2,872	2,872
Tax Expense	449	449	602	602	696	696	762	762	734	734
Current Tax	342	342	374	374	462	462	619	619	844	844
Deferred Tax	107	107	228	228	234	234	143	143	-110	-110
Effective Tax %	36.62%	36.62%	32.59%	32.59%	29.59%	29.59%	28.51%	28.51%	25.56%	25.56%
Total Profit for Period	777	777	1,245	1,245	1,656	1,656	1,911	1,911	2,138	2,138
Less: Non-controlling Interests	0	0	0	0	0	0	0	0	-25	-25
Net Profit (Owner's PAT)	777	777	1,245	1,245	1,656	1,656	1,911	1,911	2,163	2,163
Net Profit Margin %	9.13%	9.13%	12.94%	12.94%	15.44%	15.44%	16.59%	16.59%	15.47%	15.47%
PAT Growth YoY %	-37.94%	-37.94%	60.23%	60.23%	33.01%	33.01%	15.4%	15.4%	13.19%	13.19%
Earnings Per Share (EPS)	₹22.96	₹22.96	₹36.79	₹36.79	₹48.93	₹48.93	₹56.46	₹56.46	₹63.91	₹63.91
Diluted Shares Outstanding (Cr.)	34	34	34	34	34	34	34	34	34	34
Other Comprehensive Income (Net of Tax)	12	12	-137	-137	17	17	-93	-93	-180	-180
Expenses	7,479	7,479	7,818	7,818	8,434	8,434	8,866	8,866	11,014	11,014
Material Cost %	18.08%	18.08%	15.38%	15.38%	15.45%	15.45%	13.2%	13.2%	12.58%	12.58%
Employee Cost %	17.94%	17.94%	17.44%	17.44%	18.49%	18.49%	19.13%	19.13%	19.11%	19.11%
Other Cost %	24.78%	24.78%	24.58%	24.58%	25.07%	25.07%	24.45%	24.45%	24.05%	24.05%
Interest Coverage (x)	6.94	6.94	6.41	6.41	7.23	7.23	11.61	11.61	8.94	8.94

Showing the most recent 10 of 18 reported periods.

TORRENT PHARMACEUTICALS L balance sheet

Assets, liabilities and shareholders' equity as reported, in Schedule III order. Figures in ₹ crore unless a row states otherwise.

TORRENT PHARMACEUTICALS L annual balance sheet with assets, liabilities and equity. Figures in ₹ crore unless a row states otherwise.
Line item	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Equity	4,724	4,824	5,838	5,953	6,198	6,856	7,591	17,585
Equity Share Capital	85	85	85	85	169	169	169	169
Reserves & Surplus	4,639	4,739	5,753	5,868	6,029	6,687	7,422	8,220
Total Equity	4,724	4,824	5,838	5,953	6,198	6,856	7,591	17,585
Non-Current Liabilities	4,231	3,732	3,346	2,732	3,367	2,779	2,682	18,384
Long-term Borrowings	3,913	3,304	2,941	2,123	2,496	1,604	1,192	11,651
Deferred Tax Liabilities	7	—	—	194	402	656	829	5,670
Non-Current Provisions	289	338	370	369	393	445	501	765
Other Non-Current Liabilities	7	8	5	4	2	1	—	22
Non-Current Financial Liabilities	3,928	3,386	2,971	2,165	2,570	1,677	1,352	11,927
Current Liabilities	5,166	5,482	4,891	4,415	5,447	5,426	4,717	8,343
Short-term Borrowings	934	1,091	704	1,895	2,801	2,334	1,834	3,147
Trade Payables	2,098	2,076	2,067	1,674	1,679	2,089	1,820	2,358
Current Financial Liabilities	4,555	4,921	4,278	3,863	4,919	4,728	4,077	7,547
Other Current Financial Liabilities	1,523	1,754	1,507	294	439	305	423	2,042
Other Current Liabilities	118	107	128	99	103	130	136	176
Current Provisions	414	419	431	411	394	400	408	499
Current Tax Liabilities	79	35	54	42	31	168	96	121
Total Liabilities	9,397	9,214	8,237	7,147	8,814	8,205	7,399	26,727
Total Non-Current Assets	9,083	9,029	8,551	7,805	9,683	9,450	9,367	34,919
Property, Plant & Equipment (PPE)	2,801	2,953	2,884	2,703	2,772	3,297	3,455	4,909
Capital Work-in-Progress	479	577	745	544	688	281	367	457
Intangible Assets	4,612	4,238	3,840	3,461	5,012	4,503	4,152	24,280
Investment Property	—	—	—	—	—	—	—	13
Non-Current Investments	2	2	42	42	43	32	44	83
Loans – Non-Current	3	2	2	2	2	3	3	3
Other Non-Current Assets	197	220	80	148	158	324	268	258
Non-Current Financial Assets	151	131	96	111	94	72	80	130
Net Fixed Assets	7,892	7,768	7,469	6,708	8,472	8,081	7,974	29,646
Total Current Assets	5,038	5,007	5,522	5,165	5,314	5,611	5,623	9,392
Inventories	1,935	2,148	2,681	2,462	2,230	2,279	2,541	3,138
Trade Receivables	1,436	1,649	1,523	1,633	1,944	1,844	1,867	3,031
Cash & Cash Equivalents	589	662	573	398	508	835	573	1,117
Current Investments	351	—	139	184	156	141	112	866
Loans – Current	4	4	3	3	2	3	5	5
Current Financial Assets	2,672	2,401	2,390	2,391	2,781	3,028	2,746	5,625
Other Current Assets	431	458	451	312	303	304	336	629
Other Current Financial Assets	65	82	121	168	108	201	183	558
Assets Held for Sale	—	2	2	130	15	—	—	1
Net Working Capital	-128	-475	631	750	-133	185	906	1,049
Additional Asset Fields	370	433	421	494	544	555	595	9,894
Def Tax Assets	370	433	421	494	544	555	595	698
Non Controlling Int	—	—	—	—	—	—	—	9,196
Total Assets	14,121	14,038	14,075	13,100	15,012	15,061	14,990	44,312
Total Borrowings	4,847	4,395	3,645	4,018	5,297	3,938	3,026	14,798
Net Debt	4,258	3,733	3,072	3,620	4,789	3,103	2,453	13,681
Debt to Equity (x)	1.03	0.91	0.62	0.67	0.85	0.57	0.4	0.84
Current Ratio (x)	0.98	0.91	1.13	1.17	0.98	1.03	1.19	1.13

TORRENT PHARMACEUTICALS L cash flow statement

Cash generated and used across operating, investing and financing activities. Figures in ₹ crore unless a row states otherwise.

TORRENT PHARMACEUTICALS L annual cash flow statement across operating, investing and financing activities. Figures in ₹ crore unless a row states otherwise.
Line item	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Net Cash from Operating Activities	1,803	2,368	3,266	2,585	3,023
Profit Before Tax	1,226	1,847	2,352	2,673	2,872
Depreciation & Amortisation	662	707	808	795	1,119
Finance Costs	255	333	353	252	385
Working Capital Changes	-353	-18	418	-481	-342
Tax Paid	-421	-398	-498	-603	-809
Net Cash from Investing Activities	-198	-2,356	-168	-540	-12,713
Purchase of PPE	-203	-574	-433	-611	-677
Sale of Fixed Assets	6	159	134	18	41
Interest Received	7	13	13	20	36
Net Cash from Financing Activities	-1,781	77	-2,779	-2,298	10,151
Proceeds from Borrowings	219	2,237	0	0	12,594
Repayment of Borrowings	-1,033	-972	-1,369	-926	-672
Interest Paid	-258	-303	-371	-262	-427
Dividend Paid	-677	-863	-1,015	-1,083	-1,289
Buyback / Redemption of Shares	0	0	0	0	0
Lease Liabilities Paid	0	-22	-24	-27	-55
Net Change in Cash	-175	110	327	-262	544
Effect of Foreign Exchange Changes	1	21	8	-9	83
Free Cash Flow	1,600	1,794	2,833	1,974	2,346
CFO / PBT (x)	1.47	1.28	1.39	0.97	1.05

TORRENT PHARMACEUTICALS L key ratios

Valuation, profitability, return, leverage and per-share measures computed from reported statements — not from adjusted or normalised earnings.

TORRENT PHARMACEUTICALS L trades at a P/E of 74.80× against a sector median of 41.20× — a 82% premium. Sector comparisons can mislead for conglomerates with mixed business lines.

TORRENT PHARMACEUTICALS L valuation, profitability, return and leverage ratios
Ratio	Category	Value
P/E (TTM)	Valuation	74.8
Forward P/E	Valuation	47.03
P/B	Valuation	8.41
PEG (TTM)	Valuation	2.08
EV / EBITDA (TTM)	Valuation	29.63
P/S (TTM)	Valuation	11.86
Operating margin	Profitability	23.3%
Net margin (TTM)	Profitability	15.73%
Return on equity	Return ratios	12.16%
Return on capital employed	Return ratios	7.17%
Return on assets	Return ratios	7.25%
Debt to equity	Leverage & liquidity	0.84
Beta	Leverage & liquidity	0.43
EPS (TTM)	Per share	₹14.04
Book value	Per share	₹462.32
Revenue / share (TTM)	Per share	₹406.36
Cash flow / share	Per share	₹89.31
Dividend yield	Shareholder returns	0.83%
Dividend payout (TTM)	Shareholder returns	69.02%

How this is calculated

Statements are as filed with the exchanges. Consolidated figures are shown where reported. Figures are in rupees crore unless the table states otherwise. Ratios are computed from the same reported statements, not from adjusted or normalised earnings.

Index membership reflects the Nifty 100 as published by NSE Indices, effective 2026-03-30.

TORRENT PHARMACEUTICALS L: frequently asked questions

What is TORRENT PHARMACEUTICALS L's annual revenue?

TORRENT PHARMACEUTICALS L reported revenue of ₹13,980 crore in May 2026, up 0.0% on the previous financial year.

Is TORRENT PHARMACEUTICALS L profitable?

TORRENT PHARMACEUTICALS L reported a net profit of ₹2,163 crore in May 2026, up 0.0% on the previous financial year.

What is TORRENT PHARMACEUTICALS L's EPS?

TORRENT PHARMACEUTICALS L reported earnings per share of ₹63.91 for May 2026.

What is TORRENT PHARMACEUTICALS L's operating margin?

TORRENT PHARMACEUTICALS L's operating margin for May 2026 was 32.61%.

What is TORRENT PHARMACEUTICALS L's return on equity?

TORRENT PHARMACEUTICALS L's return on equity stands at 12.16%. ROE measures profit generated per rupee of shareholder equity.

How many years of TORRENT PHARMACEUTICALS L financials are shown?

18 reported financial years are tabulated on this page, the most recent being May 2026.

Are these figures consolidated or standalone?

Consolidated figures are shown wherever the company reports them, and standalone otherwise. The basis in use is labelled on the statement table.

More TORRENT PHARMACEUTICALS L data

Compare financial statements with peers

Explore

Comparing financial statements across companies is more useful than reading one in isolation — the peer links above open the same view for TORRENT PHARMACEUTICALS L’s closest listed competitors.

Disclaimer

The data, ratios and commentary about TORRENT PHARMACEUTICALS L (TORNTPHARM) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.